{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    10,
    12
  ],
  "modelUsed": "gemini-3-flash-preview",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "2",
        "name": "Amendment 2",
        "scope": {
          "id": "33764905-e3c3-482d-8af2-b76536fe1c31",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "3700efa0-cb09-45fe-9b82-9c5a29ef60d7",
          "code": {
            "id": "01923b9d-f31d-4722-9243-5e65c6974f14",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "8089b767-7793-41f1-b93e-d9a2129ce7c9",
            "type": {
              "id": "3f78913c-fed3-44e0-adb7-7e21fc06f001",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Protocol GR41984 has been amended primarily to increase the patient sample size. Changes include language to allow exploratory substudies, adjustments to ensure adequate power for the primary endpoint due to extenuating circumstances such as the COVID-19 pandemic, clarification on missed pharmacokinetic/pharmacodynamic samples, updates to temperature monitoring during drug transit, and administrative updates to medical contacts and safety population definitions.",
        "effectiveDate": "2020-11-17",
        "reasonIds": [
          "ar_1_1",
          "ar_1_2",
          "ar_1_3",
          "ar_1_4"
        ],
        "previousVersion": "1",
        "newVersion": "2"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_2",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_3",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_4",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [
      {
        "id": "country_1",
        "name": "United States",
        "instanceType": "Country",
        "code": "US"
      },
      {
        "id": "country_2",
        "name": "China",
        "instanceType": "Country",
        "code": "CN"
      },
      {
        "id": "country_3",
        "name": "Switzerland",
        "instanceType": "Country",
        "code": "CH"
      }
    ],
    "studySites": [],
    "summary": {
      "amendmentCount": 1,
      "countryCount": 3,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "Global",
      "instanceType": "GeographicScope",
      "countryIds": [
        "country_1",
        "country_2",
        "country_3"
      ]
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "2",
        "effectiveDate": "2020-11-17",
        "summary": "Protocol GR41984 has been amended primarily to increase the patient sample size. Changes include language to allow exploratory substudies, adjustments to ensure adequate power for the primary endpoint due to extenuating circumstances such as the COVID-19 pandemic, clarification on missed pharmacokinetic/pharmacodynamic samples, updates to temperature monitoring during drug transit, and administrative updates to medical contacts and safety population definitions.",
        "previousVersion": "1",
        "newVersion": "2",
        "reasons": [
          "Scientific",
          "Operational",
          "Administrative",
          "Safety"
        ]
      }
    ],
    "geographicScope": {
      "type": "Global",
      "countries": [
        {
          "name": "United States",
          "code": "US"
        },
        {
          "name": "China",
          "code": "CN"
        },
        {
          "name": "Switzerland",
          "code": "CH"
        }
      ],
      "regions": [],
      "plannedSites": null
    },
    "sites": []
  }
}